Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways
- PMID: 24133594
- PMCID: PMC3796238
Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways
Abstract
Immune complex-mediated complement activation through the classic pathway plays a key role in the pathogenesis of lupus nephritis (LN). C4d deposition in renal tissue reflects the prognosis of systemic lupus erythematosus (SLE). The aim of the current study is to investigate the pathogenesis and clinicopathologic significance of glomerular C4d deposition in LN. We retrospectively analyzed clinical and histopathological data of 20 SLE patients with renal biopsy-proven LN and 10 non-SLE renal biopsy samples as control. LN biopsies showed varying degrees of glomerular C4d staining associated with immune complex deposits, IgG (p = 0.015), C1q (p = 0.032) and C3 (p = 0.049). 7 LN biopsies had all of C4d, C1q and C3 deposits in their glomeruli, indicative of the activation of the classical pathway, whereas 2 LN biopsies had C4d and C3 deposits without accompanying C1q deposits, indicating the activation of the lectin pathway. Glomerular C4d deposition was correlated with the LN subtype (p < 0.001). In particular, a diffusely intense and coarsely granular pattern of C4d deposition in all glomeruli was detected in class V membranous LN. However, glomerular C4d deposition was correlated with neither disease activity of SLE nor histological activity and chronicity of LN. In conclusion, the activation of the lectin pathway as well as the classical pathway seems to play a crucial role in the pathogenesis of LN. Glomerular C4d staining could be helpful for diagnosing class V membranous LN, although glomerular C4d deposition does not reflect SLE disease activity and histological activity and chronicity.
Keywords: C4d; Lupus nephritis; classical pathway; disease activity; lectin pathway.
Figures
Similar articles
-
Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.Arthritis Rheum. 2008 Aug;58(8):2460-9. doi: 10.1002/art.23662. Arthritis Rheum. 2008. PMID: 18668574
-
Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.Lupus. 2012 Jan;21(1):13-26. doi: 10.1177/0961203311422093. Epub 2011 Sep 29. Lupus. 2012. PMID: 21959138
-
The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients.Front Immunol. 2021 Jul 1;12:654652. doi: 10.3389/fimmu.2021.654652. eCollection 2021. Front Immunol. 2021. PMID: 34276649 Free PMC article.
-
Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.Lupus. 2024 Feb;33(2):111-120. doi: 10.1177/09612033231226351. Epub 2024 Jan 16. Lupus. 2024. PMID: 38227433 Review.
-
C4d in Native Glomerular Diseases.Am J Nephrol. 2019;49(1):81-92. doi: 10.1159/000496059. Epub 2019 Jan 4. Am J Nephrol. 2019. PMID: 30612132 Review.
Cited by
-
Renal C4d is a potential biomarker of disease activity and severity in pediatric lupus nephritis patients.Front Pediatr. 2023 Jun 1;11:1193917. doi: 10.3389/fped.2023.1193917. eCollection 2023. Front Pediatr. 2023. PMID: 37325343 Free PMC article.
-
Role of C4d in the Diagnosis and Prognosis of Native Renal Diseases.Indian J Nephrol. 2022 Mar-Apr;32(2):97-103. doi: 10.4103/ijn.IJN_251_20. Epub 2022 Mar 11. Indian J Nephrol. 2022. PMID: 35603116 Free PMC article.
-
C4d as a Screening Tool and an Independent Predictor of Clinical Outcomes in Lupus Nephritis and IgA Nephropathy.Front Med (Lausanne). 2022 Jan 31;9:832998. doi: 10.3389/fmed.2022.832998. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35174193 Free PMC article.
-
Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.Adv Immunol. 2021;152:1-81. doi: 10.1016/bs.ai.2021.09.001. Epub 2021 Nov 19. Adv Immunol. 2021. PMID: 34844708 Free PMC article. Review.
-
Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis.Rheumatology (Oxford). 2020 Dec 1;59(12):3751-3758. doi: 10.1093/rheumatology/keaa174. Rheumatology (Oxford). 2020. PMID: 32413140 Free PMC article.
References
-
- Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton) 2005;10:174–179. - PubMed
-
- Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita H, Toki A, Horikoshi S, Ohi H, Matsushita M, Tomino Y. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011;20:1378–1386. - PubMed
-
- Manzi S, Ahearn JM, Salmon J. New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus. Lupus. 2004;13:298–303. - PubMed
-
- Batal I, Liang K, Bastacky S, Kiss LP, McHale T, Wilson NL, Paul B, Lertratanakul A, Ahearn JM, Manzi SM, Kao AH. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. Lupus. 2012;21:13–26. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous